| Name | Title | Contact Details |
|---|
Argo Group is a U.S.-focused underwriter of specialty insurance products in the property and casualty market. We offer a full line of products and services designed to meet the unique coverage and claims-handling needs of businesses. Since 1957, we share a firm commitment to working together with independent agents, wholesale brokers and retail brokerage partners to deliver innovative products for niche markets. Headquartered in New York, were a diverse company with multiple offices in the United States. Our belief that the companys success is linked to our employees drives our commitment to creating an environment and culture of respect where everyone can thrive. We value helping the communities around us, growing alongside our employees through innovation and creating a workplace with work-life balance. Fraud Alert Argo Group is aware of a fraud scam involving false job postings and unsolicited employment offers using our brand. These communications often include hyperlinks and request personal information. If you have any questions about the legitimacy of a job posting, please view all openings here on our website. If you are approached by someone claiming to represent Argo Group, please contact us at either (888) 864-3422 or siuconsults@argogroupus.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Cohen & Co is a professional services firm based in Cleveland, Ohio, founded in 1977. With over 800 employees across 15 offices in eight U.S. states, the firm specializes in tax, assurance, and advisory services. Its diverse client base includes privately held companies, public and private investment funds, fund advisers, and Fortune 1000 multinational enterprises. Recognized as one of the top 100 accounting firms in the United States by annual revenues, Cohen & Co fosters a disciplined culture focused on delivering results and personal commitment to clients. The firm emphasizes employee development and community involvement, partnering with institutions like Youngstown State University. Its service offerings include comprehensive tax planning, audit and assurance engagements, and consulting on business strategy and operational improvements, tailored to various industries such as investment management and multinational corporations.
Harbinger is a commercial electric vehicle (EV) company on a mission to transform an industry starving for innovation. Harbingers best-in-class team of EV, battery, and drivetrain experts have pooled their deep experience to support the growing demand for medium-duty EVs. Leveraging a foundation of proprietary, in-house developed vehicle technologies designed specifically for commercial vehicles, Harbinger is bringing a first-of-its-kind EV platform to market, priced for zero acquisition premium. Harbinger: familiar form, revolutionary foundation.